Mandate

Vinge advises Vostok New Ventures Ltd

February 25, 2019 Capital Markets and Public M&A

Vinge has advised Vostok New Ventures Ltd with capital markets related questions in light of the company’s divestment of its portfolio asset Avito, for in total USD 540 million, equivalent of approximately SEK 4,842 million, as well as in connection with the subsequent split and mandatory redemption program whereby each depository receipt holder (“SDRs”) will receive a cash consideration of SEK 25 per SDR.

In total, the company will redeem approximately 81,000,000 SDRs for a cash consideration amount of approximately SEK 2 billion. 

The redemption procedure was approved by a special general meeting in Vostok New Ventures on 14 February 2019. The redemption SDRs will be traded on Nasdaq Stockholm during the period 22 February – 7 March 2019.

Vinge’s team primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Annika Nyberg Ekenberg, Henrik Wastenson and Emelie Svanberg.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026